Evaluation of the Activity of Triazoles Against Non-fumigatus Aspergillus and Cryptic Aspergillus Species Causing Invasive Infections Tested in the SENTRY Program.

IF 3.8 4区 医学 Q2 IMMUNOLOGY Open Forum Infectious Diseases Pub Date : 2024-11-01 DOI:10.1093/ofid/ofae532
Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Abigail Klauer, Mariana Castanheira
{"title":"Evaluation of the Activity of Triazoles Against Non-<i>fumigatus Aspergillus</i> and Cryptic <i>Aspergillus</i> Species Causing Invasive Infections Tested in the SENTRY Program.","authors":"Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Abigail Klauer, Mariana Castanheira","doi":"10.1093/ofid/ofae532","DOIUrl":null,"url":null,"abstract":"<p><p>The activity of isavuconazole and other triazoles against non-<i>fumigatus</i> (non-AFM) <i>Aspergillus</i> causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017-2021 from 41 hospitals. Isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and/or internal spacer region/β-tubulin sequencing and tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. CLSI epidemiological cutoff values were applied, where available. Isavuconazole showed activity against <i>Aspergillus</i> sections <i>Flavi</i> (n <i>=</i> 122; minimum inhibitory concentration [MIC]<sub>50/90</sub>, 0.5/1 mg/L), <i>Terrei</i> (n <i>=</i> 57; MIC<sub>50/90</sub>, 0.5/0.5 mg/L), <i>Nidulantes</i> (n = 34; MIC<sub>50/90</sub>, 0.12/0.25 mg/L), <i>Versicolores</i> (n <i>=</i> 7; MIC<sub>50</sub>, 1 mg/L), and <i>Circumdati</i> (n <i>=</i> 2; MIC range, 0.12-2 mg/L). Similar activity was displayed by other triazoles against those <i>Aspergillus</i> sections. Most of the isolates from <i>Aspergillus</i> sections <i>Fumigati</i> (n <i>=</i> 9), <i>Nigri</i> (n <i>=</i> 146), and <i>Usti</i> (n <i>=</i> 12) exhibited elevated MIC values to isavuconazole (MIC<sub>50/90</sub>, 2/-, 2/4, and 2/8 mg/L), voriconazole (MIC<sub>50/90</sub>, 2/-, 1/2, and 4/8 mg/L), itraconazole (MIC<sub>50/90</sub>, 2/-, 2/4, and 8/>8 mg/L), and posaconazole (MIC<sub>50/90</sub>, 0.5/-, 0.5/1, and >8/>8 mg/L), respectively. Isavuconazole was active (MIC values, ≤1 mg/L) against <i>Aspergillus parasiticus</i>, <i>Aspergillus tamarii</i>, <i>Aspergillus nomius</i>, <i>Aspergillus nidulans</i>, <i>Aspergillus unguis</i>, <i>Aspergillus terreus</i>, <i>Aspergillus alabamensis</i>, and <i>Aspergillus hortai</i>, while isavuconazole MIC values between 2 and 8 mg/L were observed against cryptic isolates from <i>Aspergillus</i> section <i>Fumigati</i>. Isavuconazole inhibited 96.1% of <i>Aspergillus niger</i> and 80.0% of <i>Aspergillus tubingensis</i> at ≤4 mg/L, the CLSI wild-type cutoff value for <i>A niger</i>. Voriconazole, itraconazole, and posaconazole showed similar activity to isavuconazole against most cryptic species. Isavuconazole exhibited potent in vitro activity against non-AFM; however, the activity of triazoles varies among and within cryptic species.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae532"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528510/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae532","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The activity of isavuconazole and other triazoles against non-fumigatus (non-AFM) Aspergillus causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017-2021 from 41 hospitals. Isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and/or internal spacer region/β-tubulin sequencing and tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. CLSI epidemiological cutoff values were applied, where available. Isavuconazole showed activity against Aspergillus sections Flavi (n = 122; minimum inhibitory concentration [MIC]50/90, 0.5/1 mg/L), Terrei (n = 57; MIC50/90, 0.5/0.5 mg/L), Nidulantes (n = 34; MIC50/90, 0.12/0.25 mg/L), Versicolores (n = 7; MIC50, 1 mg/L), and Circumdati (n = 2; MIC range, 0.12-2 mg/L). Similar activity was displayed by other triazoles against those Aspergillus sections. Most of the isolates from Aspergillus sections Fumigati (n = 9), Nigri (n = 146), and Usti (n = 12) exhibited elevated MIC values to isavuconazole (MIC50/90, 2/-, 2/4, and 2/8 mg/L), voriconazole (MIC50/90, 2/-, 1/2, and 4/8 mg/L), itraconazole (MIC50/90, 2/-, 2/4, and 8/>8 mg/L), and posaconazole (MIC50/90, 0.5/-, 0.5/1, and >8/>8 mg/L), respectively. Isavuconazole was active (MIC values, ≤1 mg/L) against Aspergillus parasiticus, Aspergillus tamarii, Aspergillus nomius, Aspergillus nidulans, Aspergillus unguis, Aspergillus terreus, Aspergillus alabamensis, and Aspergillus hortai, while isavuconazole MIC values between 2 and 8 mg/L were observed against cryptic isolates from Aspergillus section Fumigati. Isavuconazole inhibited 96.1% of Aspergillus niger and 80.0% of Aspergillus tubingensis at ≤4 mg/L, the CLSI wild-type cutoff value for A niger. Voriconazole, itraconazole, and posaconazole showed similar activity to isavuconazole against most cryptic species. Isavuconazole exhibited potent in vitro activity against non-AFM; however, the activity of triazoles varies among and within cryptic species.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估三唑类药物对 SENTRY 计划中测试的非烟曲霉和引起侵袭性感染的隐蔽曲霉菌种的活性。
评估了异武康唑和其他三唑类药物对引起侵袭性曲霉病的非烟曲霉(非AFM)的活性。2017-2021年,从41家医院共收集到390株非AFM分离株(1株/患者)。分离物通过基质辅助激光解吸电离飞行时间质谱和/或内部间隔区/β-管蛋白测序进行鉴定,并通过临床和实验室标准协会(CLSI)肉汤微稀释法进行检测。如有 CLSI 流行病学临界值,则采用该临界值。异唑康唑对以下曲霉菌群具有活性:Flavi(n = 122;最低抑菌浓度 [MIC]50/90,0.5/1 mg/L)、Terrei(n = 57;MIC50/90,0.5/0.5 mg/L)、Nidulantes(n = 34;MIC50/90,0.12/0.25 mg/L)、Versicolores(n = 7;MIC50,1 mg/L)和Circumdati(n = 2;MIC范围,0.12-2 mg/L)。其他三唑类药物对这些曲霉菌也显示出类似的活性。来自 Fumigati(n = 9)、Nigri(n = 146)和 Usti(n = 12)曲霉菌群的大多数分离物对异唑醇的 MIC 值升高(MIC50/90、MIC50/90/90、MIC50/90/90、MIC50/90/90、MIC50/90/90、MIC50/90/90、MIC50/90/90 和 MIC50/90/90)、2/-、2/4 和 2/8 mg/L)、伏立康唑(MIC50/90、2/-、1/2 和 4/8 mg/L)、伊曲康唑(MIC50/90、2/-、2/4 和 8/>8 mg/L)和泊沙康唑(MIC50/90、0.5/-、0.5/1 和 >8/>8 mg/L)。异武康唑对寄生曲霉、塔马曲霉、诺米曲霉、尼杜兰曲霉、unguis 曲霉、赤曲霉、阿拉巴马曲霉和霍泰曲霉具有活性(MIC 值≤1 毫克/升),而异武康唑对来自 Fumigati 曲霉科的隐性分离菌的 MIC 值在 2 至 8 毫克/升之间。在≤4 毫克/升(CLSI 对黑曲霉的野生型临界值)的条件下,异唑康唑对 96.1%的黑曲霉和 80.0%的管曲霉具有抑制作用。伏立康唑、伊曲康唑和泊沙康唑对大多数隐居物种的活性与异武康唑相似。异武康唑对非黑僵菌具有很强的体外活性;不过,三唑类药物的活性在不同隐性物种之间和隐性物种内部存在差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Forum Infectious Diseases
Open Forum Infectious Diseases Medicine-Neurology (clinical)
CiteScore
6.70
自引率
4.80%
发文量
630
审稿时长
9 weeks
期刊介绍: Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.
期刊最新文献
Enterovirus D68: Genomic and Clinical Comparison of 2 Seasons of Increased Viral Circulation and Discrepant Incidence of Acute Flaccid Myelitis-Maryland, USA. Early Mortality and Health Care Costs in Patients Recently Diagnosed With Kaposi Sarcoma at the National Cancer Institute, Mexico City. Gut Microbiome in Human Melioidosis: Composition and Resistome Dynamics from Diagnosis to Discovery. Breakthrough Rectal Neisseria gonorrhoeae Infections After Meningococcal B Vaccination: Microbiological and Clinical Features. Lack of Detection of Norwalk Virus in Saliva Samples From a Controlled Human Infection Model.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1